Sentinel lymph node biopsy for high risk cutaneous squamous cell carcinoma: Case series and review of the literature

C. Renzi, A. Caggiati, T. J. Mannooranparampil, F. Passarelli, G. Tartaglione, G. M. Pennasilico, S. Cecconi, C. Potenza, P. Pasquini

Research output: Contribution to journalArticle

Abstract

Aims: Cutaneous squamous cell carcinoma (SCC) is the second most common skin cancer. The metastatic potential is generally low. However, there are subgroups of patients at higher risk, for whom sentinel lymph node biopsy (SLNB) might be useful. SLNB might allow the timely inclusion of high risk patients in more aggressive treatment protocols, sparing at the same time node-negative patients the morbidity of potentially unnecessary therapy. Our aim was to introduce the concept of SLNB for patients with high risk cutaneous SCC. Patients and methods: We examined a consecutive series of high risk cutaneous SCC patients undergoing SLNB at our large dermatological hospital, and performed a literature review and pooled analysis of all published cases of SLNB for cutaneous SCC. Results: Among the 22 clinically node-negative patients undergoing SLNB at our hospital, one patient (4.5%) showed a histologically positive sentinel node and developed recurrences during follow-up. Sentinel node-negative patients showed no metastases at a median follow-up of 17 months (range: 6-64). The incidence of positive sentinel nodes in previous reports ranged between 12.5% and 44.4%. Pooling together patients from the present and previous studies (total 83 patients), we calculated an Odds Ratio of 2.76 (95% CI 1.2-6.5; p = 0.02) of finding positive sentinel nodes for an increase in tumor size from 3 cm. Conclusions: Our case series and the pooled analysis support the concept that SLNB can be performed for high risk cutaneous SCC. Prospective multicenter studies are needed to examine the role, utility and cost-effectiveness of SLNB for this population.

Original languageEnglish
Pages (from-to)364-369
Number of pages6
JournalEuropean Journal of Surgical Oncology
Volume33
Issue number3
DOIs
Publication statusPublished - Apr 2007

Fingerprint

Sentinel Lymph Node Biopsy
Squamous Cell Carcinoma
Skin
Skin Neoplasms
Clinical Protocols
Multicenter Studies
Cost-Benefit Analysis
Odds Ratio
Prospective Studies

Keywords

  • Case series and review
  • Cutaneous squamous cell carcinoma
  • Sentinel lymph node biopsy

ASJC Scopus subject areas

  • Oncology
  • Surgery

Cite this

Renzi, C., Caggiati, A., Mannooranparampil, T. J., Passarelli, F., Tartaglione, G., Pennasilico, G. M., ... Pasquini, P. (2007). Sentinel lymph node biopsy for high risk cutaneous squamous cell carcinoma: Case series and review of the literature. European Journal of Surgical Oncology, 33(3), 364-369. https://doi.org/10.1016/j.ejso.2006.10.017

Sentinel lymph node biopsy for high risk cutaneous squamous cell carcinoma : Case series and review of the literature. / Renzi, C.; Caggiati, A.; Mannooranparampil, T. J.; Passarelli, F.; Tartaglione, G.; Pennasilico, G. M.; Cecconi, S.; Potenza, C.; Pasquini, P.

In: European Journal of Surgical Oncology, Vol. 33, No. 3, 04.2007, p. 364-369.

Research output: Contribution to journalArticle

Renzi, C, Caggiati, A, Mannooranparampil, TJ, Passarelli, F, Tartaglione, G, Pennasilico, GM, Cecconi, S, Potenza, C & Pasquini, P 2007, 'Sentinel lymph node biopsy for high risk cutaneous squamous cell carcinoma: Case series and review of the literature', European Journal of Surgical Oncology, vol. 33, no. 3, pp. 364-369. https://doi.org/10.1016/j.ejso.2006.10.017
Renzi, C. ; Caggiati, A. ; Mannooranparampil, T. J. ; Passarelli, F. ; Tartaglione, G. ; Pennasilico, G. M. ; Cecconi, S. ; Potenza, C. ; Pasquini, P. / Sentinel lymph node biopsy for high risk cutaneous squamous cell carcinoma : Case series and review of the literature. In: European Journal of Surgical Oncology. 2007 ; Vol. 33, No. 3. pp. 364-369.
@article{cfa5dcf61e714671848bf80808f286ac,
title = "Sentinel lymph node biopsy for high risk cutaneous squamous cell carcinoma: Case series and review of the literature",
abstract = "Aims: Cutaneous squamous cell carcinoma (SCC) is the second most common skin cancer. The metastatic potential is generally low. However, there are subgroups of patients at higher risk, for whom sentinel lymph node biopsy (SLNB) might be useful. SLNB might allow the timely inclusion of high risk patients in more aggressive treatment protocols, sparing at the same time node-negative patients the morbidity of potentially unnecessary therapy. Our aim was to introduce the concept of SLNB for patients with high risk cutaneous SCC. Patients and methods: We examined a consecutive series of high risk cutaneous SCC patients undergoing SLNB at our large dermatological hospital, and performed a literature review and pooled analysis of all published cases of SLNB for cutaneous SCC. Results: Among the 22 clinically node-negative patients undergoing SLNB at our hospital, one patient (4.5{\%}) showed a histologically positive sentinel node and developed recurrences during follow-up. Sentinel node-negative patients showed no metastases at a median follow-up of 17 months (range: 6-64). The incidence of positive sentinel nodes in previous reports ranged between 12.5{\%} and 44.4{\%}. Pooling together patients from the present and previous studies (total 83 patients), we calculated an Odds Ratio of 2.76 (95{\%} CI 1.2-6.5; p = 0.02) of finding positive sentinel nodes for an increase in tumor size from 3 cm. Conclusions: Our case series and the pooled analysis support the concept that SLNB can be performed for high risk cutaneous SCC. Prospective multicenter studies are needed to examine the role, utility and cost-effectiveness of SLNB for this population.",
keywords = "Case series and review, Cutaneous squamous cell carcinoma, Sentinel lymph node biopsy",
author = "C. Renzi and A. Caggiati and Mannooranparampil, {T. J.} and F. Passarelli and G. Tartaglione and Pennasilico, {G. M.} and S. Cecconi and C. Potenza and P. Pasquini",
year = "2007",
month = "4",
doi = "10.1016/j.ejso.2006.10.017",
language = "English",
volume = "33",
pages = "364--369",
journal = "European Journal of Surgical Oncology",
issn = "0748-7983",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Sentinel lymph node biopsy for high risk cutaneous squamous cell carcinoma

T2 - Case series and review of the literature

AU - Renzi, C.

AU - Caggiati, A.

AU - Mannooranparampil, T. J.

AU - Passarelli, F.

AU - Tartaglione, G.

AU - Pennasilico, G. M.

AU - Cecconi, S.

AU - Potenza, C.

AU - Pasquini, P.

PY - 2007/4

Y1 - 2007/4

N2 - Aims: Cutaneous squamous cell carcinoma (SCC) is the second most common skin cancer. The metastatic potential is generally low. However, there are subgroups of patients at higher risk, for whom sentinel lymph node biopsy (SLNB) might be useful. SLNB might allow the timely inclusion of high risk patients in more aggressive treatment protocols, sparing at the same time node-negative patients the morbidity of potentially unnecessary therapy. Our aim was to introduce the concept of SLNB for patients with high risk cutaneous SCC. Patients and methods: We examined a consecutive series of high risk cutaneous SCC patients undergoing SLNB at our large dermatological hospital, and performed a literature review and pooled analysis of all published cases of SLNB for cutaneous SCC. Results: Among the 22 clinically node-negative patients undergoing SLNB at our hospital, one patient (4.5%) showed a histologically positive sentinel node and developed recurrences during follow-up. Sentinel node-negative patients showed no metastases at a median follow-up of 17 months (range: 6-64). The incidence of positive sentinel nodes in previous reports ranged between 12.5% and 44.4%. Pooling together patients from the present and previous studies (total 83 patients), we calculated an Odds Ratio of 2.76 (95% CI 1.2-6.5; p = 0.02) of finding positive sentinel nodes for an increase in tumor size from 3 cm. Conclusions: Our case series and the pooled analysis support the concept that SLNB can be performed for high risk cutaneous SCC. Prospective multicenter studies are needed to examine the role, utility and cost-effectiveness of SLNB for this population.

AB - Aims: Cutaneous squamous cell carcinoma (SCC) is the second most common skin cancer. The metastatic potential is generally low. However, there are subgroups of patients at higher risk, for whom sentinel lymph node biopsy (SLNB) might be useful. SLNB might allow the timely inclusion of high risk patients in more aggressive treatment protocols, sparing at the same time node-negative patients the morbidity of potentially unnecessary therapy. Our aim was to introduce the concept of SLNB for patients with high risk cutaneous SCC. Patients and methods: We examined a consecutive series of high risk cutaneous SCC patients undergoing SLNB at our large dermatological hospital, and performed a literature review and pooled analysis of all published cases of SLNB for cutaneous SCC. Results: Among the 22 clinically node-negative patients undergoing SLNB at our hospital, one patient (4.5%) showed a histologically positive sentinel node and developed recurrences during follow-up. Sentinel node-negative patients showed no metastases at a median follow-up of 17 months (range: 6-64). The incidence of positive sentinel nodes in previous reports ranged between 12.5% and 44.4%. Pooling together patients from the present and previous studies (total 83 patients), we calculated an Odds Ratio of 2.76 (95% CI 1.2-6.5; p = 0.02) of finding positive sentinel nodes for an increase in tumor size from 3 cm. Conclusions: Our case series and the pooled analysis support the concept that SLNB can be performed for high risk cutaneous SCC. Prospective multicenter studies are needed to examine the role, utility and cost-effectiveness of SLNB for this population.

KW - Case series and review

KW - Cutaneous squamous cell carcinoma

KW - Sentinel lymph node biopsy

UR - http://www.scopus.com/inward/record.url?scp=33947636745&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947636745&partnerID=8YFLogxK

U2 - 10.1016/j.ejso.2006.10.017

DO - 10.1016/j.ejso.2006.10.017

M3 - Article

C2 - 17129703

AN - SCOPUS:33947636745

VL - 33

SP - 364

EP - 369

JO - European Journal of Surgical Oncology

JF - European Journal of Surgical Oncology

SN - 0748-7983

IS - 3

ER -